Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis
Key facts
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 112 people enrolled
- Started
- 7 Jun 2018
- Ended
- 21 Aug 2024
- Type of study
- Interventional
- Treatments tested
- Daptomycin
- Record updated
- 1 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Persons aged over 18 years
- With Suspected pneumococcal meningitis :; clinical presentation evocative of pneumococcal meningitis : acute onset of ,meningeal signs, history of cranial trauma or fistula, knowledge of alteration of humoral immunity,, asplenia, alcoholism with/or; clearly purulent CSF with/ or,; presence of diplococcus on the Gram stain of CSF or positive pneumococcal antigen in the CSF, or polymorphonuclear cells in CSF > 100
- Written consent or inclusion in an emergency
- Affiliation to a social security system
Who cannot take part
- Contraindication to dexamethasone
- Previous exposition to daptomycin (within one year)
- Immediate and severe hypersensitivity to β-lactam antimicrobial
- Contraindication to cephalosporin
- Contraindication to daptomycin
- Women who are able to procreate without effective contraception and pregnant or breastfeeding women
- Patients under ward of court
- Refusal at any time after acceptation of the study from the patient or her/his legal representative
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd generation cephalosporins. Nevertheless, complications associated with meningitis are relatively frequent and severe. Recent animal studies have shown that another antibiotic, daptomycin, can reduce the mortality and long-term effects of pneumococcal meningitis. Daptomycin is widely used worldwide in humans for other diseases, with few side effects.
Read full original descriptionShow less
This study aims to evaluate the effect of daptomycin on the proliferation of the bacterial infection, and therefore on inflammation. Daptomycin will be added to the currently recommended treatment with the same dosage used for other diseases.
Roughly 130 patients with suspected pneumococcal meningitis admitted to the emergency departments of hospitals throughout France will be asked to participate in this study.
The participation period will last approximately 3 months.
The group in the trial
- PatientsTreatment being tested
Treatment: Daptomycin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis: AddaMAP Study
- Publications
- Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study.BMJ open, 2023
- Acute bacterial meningitis.Current opinion in neurology, 2021
- Record updated
- 1 October 2024